University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 7 of 35

ACTIVE NOT RECRUITING

Predicting Cognitive Decline From Androgen Deprivation Therapy

NCT05820932

ACTIVE NOT RECRUITING NA

Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus

NCT05671861

ACTIVE NOT RECRUITING NA

Multiple Sclerosis Falls Insight Track

NCT05837949

ACTIVE NOT RECRUITING NA

Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study

NCT05715268

ACTIVE NOT RECRUITING NA

Neural Mechanisms of Meditation Training in Healthy and Depressed Adolescents: An MRI Connectome Study PART 2

NCT05267340

ACTIVE NOT RECRUITING NA

Restoring Metabolic and Reproductive Health With Sleep in PCOS Study, CPAP Trial

NCT05920694

ACTIVE NOT RECRUITING NA

Perinatal Research on Improving Sleep and Mental Health

NCT05596318

ACTIVE NOT RECRUITING

Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy

NCT05361070

ACTIVE NOT RECRUITING

Assessing Brain Metabolism Using MRS With Deuterated Glucose

NCT06594315

ACTIVE NOT RECRUITING Phase 2

Angiotensin II in Liver Transplantation

NCT04901169

ACTIVE NOT RECRUITING Phase 1

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

NCT05317689

ACTIVE NOT RECRUITING NA

Simultaneously Implementing Pathways for Improving Asthma, Pneumonia, and Bronchiolitis Care for Hospitalized Children

NCT05206695

ACTIVE NOT RECRUITING NA

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

NCT05593237

ACTIVE NOT RECRUITING

SKY Breath Intervention

NCT05388110

ACTIVE NOT RECRUITING NA

Collaborative Approach to Examining Adversity and Building Resilience Study

NCT05259436

ACTIVE NOT RECRUITING NA

Pilot Test of Apnea and Insomnia Relief for Veterans With Gulf War Illness

NCT05137743

ACTIVE NOT RECRUITING Phase 4

Kebele Elimination of Trachoma for Ocular Health

NCT03335072

ACTIVE NOT RECRUITING NA

Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use

NCT05191446

ACTIVE NOT RECRUITING Phase 2

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294

ACTIVE NOT RECRUITING NA

Development and Feasibility of Mindfulness Based Pain Reduction

NCT04980612

ACTIVE NOT RECRUITING NA

Watermelon/UBIQuinone Study

NCT04972552

ACTIVE NOT RECRUITING Phase 4

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712

ACTIVE NOT RECRUITING

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219

ACTIVE NOT RECRUITING

Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

NCT04602806

ACTIVE NOT RECRUITING

Social & Contextual Impact on Children Undergoing Liver Transplantation

NCT04551742

ACTIVE NOT RECRUITING Phase 4

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

NCT04466150

ACTIVE NOT RECRUITING Phase 1

Combinatorial Therapy to Induce an HIV Remission

NCT04357821

ACTIVE NOT RECRUITING NA

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents

NCT04201106

ACTIVE NOT RECRUITING

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic

NCT04388605

ACTIVE NOT RECRUITING NA

The Role of Cerebellum in Speech

NCT03972202

ACTIVE NOT RECRUITING Phase 1

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187

ACTIVE NOT RECRUITING

Attitudes and Decision-making After Pregnancy Testing Study

NCT03888404

ACTIVE NOT RECRUITING NA

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372

ACTIVE NOT RECRUITING NA

Hydrops: Diagnosing & Redefining Outcomes With Precision Study

NCT03412760

ACTIVE NOT RECRUITING NA

The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy

NCT03582891

ACTIVE NOT RECRUITING Phase 2

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

NCT03433469

ACTIVE NOT RECRUITING NA

Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)

NCT03999151

ACTIVE NOT RECRUITING

Developmental Epidemiological Study of Children Born Through Reproductive Technology

NCT03799107

ACTIVE NOT RECRUITING NA

Hand Rehabilitation Study for Stroke Patients

NCT03148106

ACTIVE NOT RECRUITING Phase 4

Secondhand Smoke Respiratory Health Study

NCT02797275

ACTIVE NOT RECRUITING NA

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

NCT02735252

ACTIVE NOT RECRUITING NA

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04669743

ACTIVE NOT RECRUITING Phase 4

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511

ACTIVE NOT RECRUITING NA

PCOS & Insulin Resistance Exercise Study

NCT02303470

ACTIVE NOT RECRUITING NA

Behavioral Research of Environment and Air Pollution Through Education

NCT02471872

ACTIVE NOT RECRUITING

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

NCT02100904

ACTIVE NOT RECRUITING NA

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

NCT01570998

ACTIVE NOT RECRUITING Phase 4

Effects of Brain Beta-Amyloid on Postoperative Cognition

NCT01606488

ACTIVE NOT RECRUITING

Mediators of Atherosclerosis in South Asians Living in America

NCT01207167

ACTIVE NOT RECRUITING

Modifiers of Disease Severity in Cerebral Cavernous Malformations

NCT01764529

← Previous Page 7 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.